Format

Send to

Choose Destination
Fertil Steril. 2019 Jul 29. pii: S0015-0282(19)30475-3. doi: 10.1016/j.fertnstert.2019.05.018. [Epub ahead of print]

Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.

Author information

1
Department of Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: ruddy.kathryn@mayo.edu.
2
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
3
Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
5
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
6
Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
7
Department of Gynecology, Klinik Bad Trissl, Oberaudorf, Germany.
8
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.
9
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
10
Department of Pharmacology, Mayo Clinic, Rochester, Minnesota.
11
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
12
Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

Abstract

OBJECTIVE:

To study how genetics may play a role in determining risk of chemotherapy-related amenorrhea (CRA) in young women with breast cancer.

DESIGN:

Genome-wide association study.

SETTING:

Not applicable.

PATIENT(S):

Premenopausal women ≤45 years of age enrolled in one of these three trials were included if they had at least one menstrual case report form after chemotherapy ended and if they were of European ancestry. Forms during and up to 3 months after receipt of GnRH agonist were excluded.

INTERVENTION(S):

None.

MAIN OUTCOME MEASURE(S):

The association of single-nucleotide polymorphisms with post-chemotherapy menstruation adjusted for trial and arm, age, tamoxifen use, and nodal status.

RESULT(S):

The median age of the 1,168 women was 41 years (range 19-45). Among these, 457 (39%) never resumed menses after chemotherapy. Older age, tamoxifen use, and node-negative disease were associated with increased risk of CRA. Adjusting for these, rs147451859, in an intron of PPCDC (phosphopantothenoylcysteine decarboxylase), and rs17587029, located 5' upstream of RPS20P11 (ribosomal protein S20 pseudogene 11), were associated with post-chemotherapy menstruation.

CONCLUSION(S):

Genetic variation may contribute to risk of CRA. Better prediction of who will experience CRA may inform reproductive and treatment decision making in young women with cancer.

KEYWORDS:

Breast neoplasms; amenorrhea; drug therapy; toxicity

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center